Shenzhen Kexing Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213...2223»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2129;    
    P2
    Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, ML210 / University of Sydney
    Journal:  Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma. (Pubmed Central) -  Apr 22, 2024   
    Taken together, our findings show firstly that eribulin triggers ferroptosis in OCCC and this effect occurs via the suppression of the Nrf2-HO-1 signaling pathway, SOD activity and the promotion of lipid peroxidation. These findings suggest that eribulin-induced ferroptosis is associated with its anti-tumor effect and also could be a potential therapeutic target in OCCC.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, Metastases:  Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells. (Pubmed Central) -  Mar 31, 2024   
    Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.
  • ||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Gilead
    Review, Journal, Metastases:  Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer. (Pubmed Central) -  Mar 26, 2024   
    Sacituzumab govitecan demonstrated an overall benefit in terms of health-related quality of life. Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer.
  • ||||||||||  ELVN-002 / Enliven Therapeutics
    Enrollment open:  ELVN-002-003: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov) -  Mar 26, 2024   
    P1,  N=255, Recruiting, 
    Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer. Not yet recruiting --> Recruiting
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) -  Mar 25, 2024   
    Not yet recruiting --> Recruiting A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
  • ||||||||||  TQB2930 / Sino Biopharm
    Enrollment change, Trial completion date, Trial primary completion date, Monotherapy:  A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) -  Mar 12, 2024   
    P1/2,  N=154, Recruiting, 
    Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted. N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
  • ||||||||||  Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date:  Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) -  Mar 12, 2024   
    P2,  N=30, Recruiting, 
    N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026 Trial completion date: May 2025 --> Aug 2027 | Trial primary completion date: Nov 2023 --> Jun 2027
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Mechanistic evaluations of the immunological and cell biological effects that distinguish eribulin from other microtubule-targeted chemotherapeutics (Section 2) -  Mar 5, 2024 - Abstract #AACR2024AACR_8205;    
    Both genetic and pharmacological inhibitors of GEF-H1 were utilized to interrogate the relationship between eribulin-mediated microtubule destabilization and TBK1/IRF3-dependent immunological activation as well as the formation of RhoA-dependent focal adhesions and reversal of EMT-associated phenotypes. Together, our data provide a mechanistic rationale for unique effects of eribulin as compared to other classes of MTAs that could inform on the use of these widely used, but mechanistically underappreciated drugs in a more personalized manner and inform on their rational combination with targeted agents, including immunotherapy.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Analysis of the effect of eribulin on tumor immunity against triple-negative breast cancer (Section 39) -  Mar 5, 2024 - Abstract #AACR2024AACR_6520;    
    Our findings suggest that eribulin can facilitate the proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells in vitro. Further analysis of the effects of eribulin on TNBC cells and immune cells in vivo is required, and we continue to analyze immunomodulation in patients treated with eribulin.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Determining the role of septin expression in response of breast cancer patients to microtubule targeted chemotherapy (Section 45) -  Mar 5, 2024 - Abstract #AACR2024AACR_6451;    
    Drugs that disrupt the microtubule cytoskeleton, including both microtubule stabilizing taxanes and destabilizers like eribulin, are regularly used in the treatment of metastatic breast cancer...These data were used to support an ongoing prospective study to determine effect of septin expression on response to taxane chemotherapy in the neoadjuvant setting and determine the effect of taxane treatment on septin expression by comparing samples pre and post treatment. Together this work supports our overall goal of identifying predictive biomarkers to facilitate the use of microtubule targeted chemotherapy in a more personalized manner.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
    Sensitization to chemo-immunotherapy by targeting TGF-? in preclinical triple negative breast cancer models (Section 47) -  Mar 5, 2024 - Abstract #AACR2024AACR_2435;    
    The IMpassion 130 trial demonstrated the efficacy of nab-paclitaxel and atezolizumab (anti-PD-L1) in PD-L1+ patients, but unfortunately, IMpassion 131 with paclitaxel did not replicate these results...Optimizing chemo-immunotherapy combinations is a major challenge in the management of TNBC.The initial aim of this project was to evaluate the immune effects of an experimental chemotherapy doublet, based on two drugs used in mTNBC: cisplatin (CDDP) and eribulin...The results show that inhibition of TGF-?, combined with chemo-immunotherapy in the 4T1 model, leads to a reduction in tumor immunosuppression and intratumoral fibrosis, as well as an increase in CTL infiltration and cytotoxicity, enabling tumor sensitization.Overall, this project highlights the benefits of using an experimental doublet of CDDP and eribulin-based chemotherapies. This project demonstrates that management of chemo-induced immunosuppression mechanisms is necessary to overcome tumor resistance to immunotherapy.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
    Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker:  A Case of Triple Negative Breast Cancer with Successful Control of Recurrent Disease Activity for More than Ten Years (Pubmed Central) -  Feb 6, 2024   
    Applicable regimens of drug therapy are still available at present and drug therapy has been continued based on a discussion and mutual understanding of the adverse reactions, etc. with the patient. Few reports have been published concerning long-term survivors among TN breast cancer cases.